Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Rating) – Equities research analysts at Oppenheimer boosted their FY2022 earnings estimates for Seres Therapeutics in a research note issued to investors on Wednesday, November 2nd. Oppenheimer analyst M. Breidenbach now expects that the biotechnology company will post earnings of ($2.26) per share for the year, up from their prior forecast of ($2.33). The consensus estimate for Seres Therapeutics' current full-year earnings is ($2.22) per share. Oppenheimer also issued estimates for Seres Therapeutics' Q4 2022 earnings at ($0.50) EPS, Q1 2023 earnings at ($0.50) EPS, Q3 2023 earnings at ($0.40) EPS, Q4 2023 earnings at ($0.39) EPS, FY2023 earnings at ($0.78) EPS, FY2024 earnings at ($1.07) EPS, FY2025 earnings at ($1.17) EPS and FY2026 earnings at ($0.94) EPS.
Get
Seres Therapeutics alerts:
Seres Therapeutics (NASDAQ:MCRB – Get Rating) last issued its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.04). Seres Therapeutics had a negative return on equity of 305.32% and a negative net margin of 1,729.94%. The firm had revenue of $3.44 million for the quarter, compared to analyst estimates of $12.29 million.
A number of other analysts also recently commented on the stock. StockNews.com downgraded shares of Seres Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday. Chardan Capital decreased their price objective on shares of Seres Therapeutics from $16.00 to $12.00 in a report on Thursday, August 4th. Finally, Piper Sandler boosted their price objective on shares of Seres Therapeutics from $7.00 to $9.00 and gave the stock an "overweight" rating in a report on Wednesday, September 7th.
Seres Therapeutics Trading Down 9.5 %
Shares of Seres Therapeutics stock opened at $8.14 on Monday. Seres Therapeutics has a 52-week low of $2.50 and a 52-week high of $11.69. The company has a quick ratio of 2.35, a current ratio of 3.03 and a debt-to-equity ratio of 0.75. The company's 50-day simple moving average is $6.61 and its 200-day simple moving average is $4.94. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -3.46 and a beta of 2.81.
Insider Buying and Selling at Seres Therapeutics
In related news, insider David S. Ege sold 5,012 shares of the company's stock in a transaction that occurred on Monday, October 31st. The shares were sold at an average price of $7.93, for a total transaction of $39,745.16. Following the transaction, the insider now owns 46,734 shares of the company's stock, valued at $370,600.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.20% of the company's stock.
Hedge Funds Weigh In On Seres Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of MCRB. Great West Life Assurance Co. Can purchased a new position in shares of Seres Therapeutics during the third quarter valued at approximately $27,000. Y Intercept Hong Kong Ltd acquired a new position in Seres Therapeutics during the second quarter worth approximately $49,000. Centiva Capital LP acquired a new position in Seres Therapeutics during the second quarter worth approximately $50,000. Allspring Global Investments Holdings LLC acquired a new position in Seres Therapeutics during the first quarter worth approximately $52,000. Finally, Victory Capital Management Inc. acquired a new position in Seres Therapeutics during the third quarter worth approximately $68,000. Hedge funds and other institutional investors own 96.09% of the company's stock.
About Seres Therapeutics
(Get Rating)
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI).
Featured Stories
- Get a free copy of the StockNews.com research report on Seres Therapeutics (MCRB)
- After Doubling, First Solar May Keep Shining
- Barrick Gold is a Hold as Long as Gold Prices Stay Stagnant
- MarketBeat: Week in Review 10/31-11/4
- Is Hershey's a Sweet Stock to Buy After a Post-Earnings Dip?
- Datadog Doesn't Belong In The Doghouse
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
